Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.44 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.44 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417331 | 0.84 | ADORA3 (0.60) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL5777076 | 0.84 | PDE5A (0.48) | PDE5AADORA3KCNH2 | |
| SCHEMBL29382996 | 0.84 | ADORA3 (0.60) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL5777620 | 0.84 | PDE5A (0.52) | PDE5AADORA3KCNH2 | |
| SCHEMBL5775598 | 0.83 | PDE5A (0.49) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL5779816 | 0.83 | PDE5A (0.49) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL18496415 | 0.83 | PDE5A (0.59) | PDE5AADORA3KCNH2 | |
| SCHEMBL5775370 | 0.81 | PDE5A (0.56) | PDE5AADORA3KCNH2 | |
| SCHEMBL5777230 | 0.81 | ADORA3 (0.51) | PDE5AADORA3KCNH2 | |
| SCHEMBL15087585 | 0.80 | ADORA3 (0.58) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531187-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | Bayer Intellectual Property GmbH (DE) | 2012-12-12 | — | — | EP | claimed |
| WO-2011095534-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | claimed |
| EP-3525779-A1 | COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-2531187-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | Bayer Intellectual Property GmbH (DE) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095534-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | disclosed |